Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.